Prevalence: The prevalence of pituitary tumors has been a topic of controversy for many years. Autopsy and radiological series show that pituitary incidentalomas may be present in one of six people. Recent epidemiological data suggest that clinically apparent pituitary adenomas have a prevalence of approximately one in 1,000 people in the general population. The disconnect between these two prevalence rates underlines the common clinical quandary of how to manage pituitary incidentalomas, particularly those lacking clinical signs/symptoms or hormonal abnormalities. Management: The natural history of incidentalomas suggests that periodic hormonal, clinical and radiological follow-up is the optimal approach. In the absence of tumor growth or relevant symptoms, screening can be continued intermittently or curtailed based on the clinical judgment of the physician. In the presence of hormonal hypersecretion, the management of pituitary incidentalomas, whether they are micro- or macroadenomas, should follow accepted clinical guidelines. For incidental pituitary macroadenomas without hormonal hypersecretion, clinical management should also include assessments for visual field impairment or hypopituitarism. In such cases, regular radiological and hormonal follow-up is required to identify tumor growth or the appearance of new symptoms. In the presence of tumor growth or new hormonal abnormalities, surgical options should be considered and discussed with the patient.

Keywords:
Pituitary incidentalomas, Prevalence, Epidemiology
1.
CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1998–2002. The Central Brain Tumor Registry of the United States. 2005. Available at: http://www.cbtrus.org/reports//2005-2006/2006report.pdf.
2.
Finnish Cancer Registry. Cancer in Finland 2005–2006. Cancer Society of Finland. Available at: www.cancerregistry.fi.
3.
Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T: Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol 2001;3:152–158.
4.
Davis JR, Farrell WE, Clayton RN: Pituitary tumours. Reproduction 2001;121:363–371.
5.
Ambrosi B, Faglia G: Epidemiology of pituitary tumors; in Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A (eds): Pituitary Adenomas: New Trends in Basic and Clinical Research. Amsterdam, Elsevier, 1991, pp 159–168.
6.
Costello RT: Subclinical adenoma of the pituitary gland. Am J Pathol 1936;12:205–214.
7.
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE: The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613–619.
8.
Daly A, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A: High prevalence of pituitary adenomas: a cross sectional study in the Province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769–4775.
9.
Sanno N, Oyama K, Tahara S, Teramoto A, Kato Y: A survey of pituitary incidentaloma in Japan. Eur J Endocrinol 2003;149:123–127.
10.
Chanson P, Daujat F, Young J, Bellucci A, Kujas M, Doyon D, Schaison G: Normal pituitary hypertrophy as a frequent cause of pituitary incidentaloma: a follow-up study. J Clin Endocrinol Metab 2001;86:3009–3015.
11.
Shin JL, Asa SL, Woodhouse LJ, Smyth HS, Ezzat S: Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke’s cleft cyst, and arachnoid cyst. J Clin Endocrinol Metab 1999;84:3972–3982
12.
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265–273.
13.
Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A, Acromegaly Treatment Consensus Workshop Participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054–4058.
14.
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M: Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593–5602.
15.
Fainstein Day P, Guitelman M, Artese R, Fiszledjer L, Chervin A, Vitale NM, Stalldecker G, De Miguel V, Cornalo D, Alfieri A, Susana M, Gil M: Retrospective multicentric study of pituitary incidentalomas. Pituitary 2004;7:145–148.
16.
Feldkamp J, Santen R, Harms E, Aulich A, Modder U, Scherbaum WA: Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas – results of a prospective study. Clin Endocrinol (Oxf) 1999;51:109–113.
17.
Reincke M, Allolio B, Saeger W, Menzel J, Winkelmann W: The ‘incidentaloma’ of the pituitary gland. Is neurosurgery required? JAMA 1990;263:2772–2776.
18.
Donovan LE, Corenblum B: The natural history of the pituitary incidentaloma. Arch Intern Med 1995;155:181–183.
19.
Molitch ME: Clinical review 65. Evaluation and treatment of the patient with a pituitary incidentaloma. J Clin Endocrinol Metab 1995;80:3–6.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.